Veracyte, Inc. (VCYT)

Market Cap	2.84B -16.9%
Revenue (ttm)	495.14M +16.4%
Net Income	30.32M
EPS	0.38
Shares Out	79.05M
PE Ratio	95.13
Forward PE	24.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,213
Open	35.77
Previous Close	36.19
Day's Range	35.55 - 35.86
52-Week Range	22.61 - 50.71
Beta	1.91
Analysts	Strong Buy
Price Target	46.00 (+28.1%)
Earnings Date	Feb 25, 2026

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 824
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Analyst Summary

According to 8 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price target is $46.0, which is an increase of 28.10% from the latest price.

Price Target

$46.0

(28.10% upside)

Analyst Consensus: Strong Buy